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e-mail address: fsaikhan@hotmail.comFahad I. Al-Saikhan, Pharm. D ⇑AbstractThe advances in gene therapy hold significant promise for the treatment of ophthalmic conditions. Several studies using animal
models have been published. Animal models on retinitis pigmentosa, Leber’s Congenital Amaurosis (LCA), and Stargardt disease
have involved the use of adeno-associated virus (AAV) to deliver functional genes into mice and canines. Mice models have been
used to show that a mutation in cGMP phosphodiesterase that results in retinitis pigmentosa can be corrected using rAAV vectors.
Additionally, rAAV vectors have been successfully used to deliver ribozyme into mice with a subsequent improvement in autosomal
dominant retinitis pigmentosa. By using dog models, researchers have made progress in studying X-linked retinitis pigmentosa
which results from a RPGR gene mutation. Mouse and canine models have also been used in the study of LCA. The widely studied
form of LCA is LCA2, resulting from a mutation in the gene RPE65. Mice and canines that were injected with normal copies of
RPE65 gene showed signs such as improved retinal pigment epithelium transduction, visual acuity, and functional recovery. Studies
on Stargardt disease have shown that mutations in the ABCA4 gene can be corrected with AAV vectors, or nanoparticles. Gene
therapy for the treatment of red–green color blindness was successful in squirrel monkeys. Plans are at an advanced stage to begin
clinical trials. Researchers have also proved that CD59 can be used with AMD. Gene therapy is also able to treat primary open angle
glaucoma (POAG) in animal models, and studies show it is economically viable.
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Gene therapy refers to the use of genes to treat various
medical conditions. The concept involves transferring genetic
material into cells, tissues or organs with the aim of curing a
disease or improving the clinical status of a patient. The cen-
tral goal of gene therapy is to replace genes that are non-
functional or defective with new genes that are fully-func-
tional so that the level of genetic expression can return to
normal.1 Some of the latest breakthroughs in the field of
gene therapy have been its potential applications in the
treatment of a wide range of ophthalmic conditions. Mostof the work has focused on the retina which has been shown
to be an ideal target especially for the adeno-associated viral
(AAV) vector (What is gene therapy? 2012). AAV is a vector
that infects the retinal cells quite effectively (Fig. 1). Injection
of AAV under the retina entails vitrectomy, which is a stan-
dard surgical procedure. After vitrectomy, a very narrow nee-
dle is used to inject the vector under the retina (Fig. 2). The
AAV is contained in approximately 1/10th of a milliliter of
fluid.2 The need for gene therapy is based on the clinical
characteristics of an ophthalmic condition. The Gene Therapy
Center facilitates both genetic research and gene therapy.
Gene therapy trials require approval by the Food and Druge:
al.com
ty. P.O.
Figure 1. Image showing how AAV vector is used to mediate gene transfer. (Source: see Ref. 9).
Figure 2. Image showing how DNA or RNA is introduced into the desired site in the retina during gene therapy. (Source: see Ref. 12).
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National Institutes of Health (NIH) must be recognized by
the NIH Recombinant DNA Advisory Committee (RAC).3
Given the many success stories in the application of gene
therapy in ophthalmology, this paper shall give a review of
the ongoing research in this area with special reference to
six ophthalmic conditions; retinitis pigmentosa, Leber’s
Congenital Amaurosis (LCA), Stargardt disease, red–green
color blindness, age related macular degeneration (AMD),
and primary open angle glaucoma (POAG).Gene therapy for the treatment of ophthalmic
conditions
Retinitis pigmentosa (RP)
Retinitis pigmentosa (RP) belongs to a group of eye dis-
eases caused by multiple mutations in the gene that encodes
rhodopsin. Rhodopsin is an essential pigment that facilitatesthe cascade for visual transduction. Visual transduction is the
process that enables vision in bright and poorly-lit
conditions.4 A mutation in the rhodopsin gene results in a
progressive depletion of photoreceptor cells that are respon-
sible for changing light energy into nerve signals. The pro-
gressive breakdown of these cells is accompanied by a
gradual loss of vision which may initially start with night blind-
ness and progress to total blindness.5 Both rods and cones
are photoreceptor cells. Rods are active during mesopic
and scotopic conditions whereas cones are active during
photopic conditions and for color detection.6
As RP occurs due to gene mutations, researchers have con-
centrated on using gene therapy to correct the defective
genes. Two approaches have been used; the first approach is
to transfer a properly functioning copy of the affected gene
using AAV into the retina. Alternatively, researchers can inacti-
vate a mutated gene responsible for the production of a gene
product that has deleterious effects on photoreceptors.7
Significant success has been achieved by using AAV to
mediate transgene expression in the retinal tissue i.e. the
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of AAV to facilitate the transfer of reporter genes to the retina
has paved way for recombinant adeno-associated viral (rAAV)
vectors in the treatment of retinal degeneration (Fig. 1).8
Nagatsu et al.8 conducted tests on the potential applica-
tion of rAAV vectors in the treatment of recessive RP due
to a mutation in cGMP phosphodiesterase (PDE). They found
that after intraocular delivery of the correct PDE into a mouse
model that was PDE recessive, photoreceptor cells were pro-
tected from degeneration while retinal function was
preserved.8
Autosomal dominant RP (ADRP) is another form of RP in
which AAV vectors have been shown to have a remarkable
therapeutic potential. ADRP is caused by a defective rhodop-
sin gene product that leads to photoreceptor cells’ death
which eventually leads to blindness.10 Nagatsu et al.8 showed
that rAAV vectors can deliver ribozyme specifically designed
to cut and destroy the mRNA of the defective rhodopsin
gene. By using a transgenic rat model of ADRP, Lewin et al.
noted reduced degeneration of photoreceptor cells follow-
ing the delivery of the ribozyme.8
In a recent study, researchers investigated the potential of
gene therapy in the treatment of X-linked RP (XLRP). The
most prevalent form of XLRP results from a RP GTPase Reg-
ulator (RPGR) gene mutation, found in the X chromosome
(Beltran et al., 2012). In dogs, this disorder is known as
X-linked progressive retinal atrophy (XLPRA), which also ema-
nates from a RPGR gene mutation. By using dog models,
researchers used AAV vectors to inject one eye of the exper-
imental dogs with a normal RPGR gene from humans. The
solution containing the vector was targeted at the space be-
tween the retinal pigment epithelial layer and the photore-
ceptor cell layer (Fig. 2).11 The other eye was not injected
with AAV vector solution and thus served as a control.11
The eyes that had received AAV vector solution showed a
resumption of normal RPGR gene expression in the photore-
ceptors. In addition, the treated areas showed no further ret-
inal degeneration. Retinal thickness was near normal limits in
the treated region while the retina in untreated regions be-
came thinner.11 This study provided a firm foundation for
the application of a similar approach in humans.Leber’s Congenital Amaurosis (LCA)
LCA is an autosomal recessive disease resulting from muta-
tions in different genes, 15 of which have been reported to
date.13 Patients with LCA manifest with fundus abnormality
on ophthalmoscopy, impaired pupillary light reflexes, se-
verely reduced electroretinograms, and nystagmus.14 Addi-
tionally there is progressively degenerating cellular structure
of the retina and severe visual loss and retinal functions. Many
studies have investigated the role of gene therapy for the
treatment of LCA type 2 (LCA2). LCA2 is associated with
mutations in the RPE65 gene (S, L and K 2011). Mutation in
this gene causes a deficiency retinoid isomerohydrolase,
which facilitates proper functioning of photoreceptors.15
Canine, porcine and rodent models have been used to
show that rAAV can deliver functional retinoid isomerohydro-
lase with the goal of preventing retinal degeneration and
restoring visual function.16 The outcomes of this preclinical
trial16 has led to a cooperative effort by Pennsylvania Univer-
sity and Applied Genetic Technologies to develop a rAAVvector with the capacity to express human retinoid isomero-
hydrolase with a chicken beta-actin promoter being used to
control expression. Following the administration of rAAV2-
CBS-hRPE65 in young adult pigs with LCA2, there was im-
proved visual function in the long term with no indication of
an adverse immunogenic response.16
rAAV vectors carrying RPE65 cDNA have been used to
treat mice with Rpe65 gene mutation at different stages of
development. Cai et al.17 found that treatment outcomes
irrespective of the stage of development indicated efficient
retinal pigment epithelium (RPE) transduction.17 In addition,
the expression of the injected RPE65 protein could be de-
tected even 7 months after injection via immunohistochemis-
try.17 The treated mice also showed nearly normal retinal
morphology and almost normal levels of retinyl-esters and
rhodopsin.17 Visual acuity also improved, and remarkable
functional rescue was also noted.17
Swedish Briard dog models have also been used to dem-
onstrate the potential therapeutic implications of gene
replacement therapy in LCA2.17 In a study by Cai et al.17 sev-
eral dogs at different ages were each administered with a sin-
gle injection of rAAV carrying functional RPE65 gene. The
results indicated significant improvement in visual function,
visual behavior, and retinoid content.17 Two weeks following
treatment, functional recovery was clearly evident and
peaked 3 months after the injection.17 Functional rescue
went beyond 7 years in treated dogs.17
The success seen in animal studies has prompted a team
of scientists in London to initiate the first gene therapy trial
on humans with LCA. Twelve people with impending blind-
ness due to LCA underwent injections of rAAV vectors carry-
ing the wildtype RPE65 gene into their retinal cells. The
physicians also injected normal copies of RPE65 gene directly
into the cells of the retina and noted production of wildtype
RPE65 proteins.18 There is, therefore, much hope that gene
therapy will work in humans with LCA at some point.Stargardt disease
Stargardt disease causes retinal degeneration following
mutations in a gene called ATP-binding cassette sub-family
A member 4 (ABCA4; ABCR). The gene ABCA4 encodes a
protein responsible for transportation of energy between
photoreceptor cells and the retina. A mutation therefore,
causes the degeneration of photoreceptor cells, which even-
tually leads to vision loss.19 A number of rodent models
mostly using mice have been conducted and promising re-
sults have been accumulated.20 For example, Dr. Muna
Naash on August 17, 2012 used nanoparticles to transfer nor-
mal copies of ABCA4; ABCR gene into mice. This process re-
sulted in long-term preservation of vision in mice with
Stargardt disease.21 The outcomes from mice models lay
the foundation for further research in how similar approaches
can be used to treat Stargardt disease in humans. Nanopar-
ticles are advantageous due to the lower likelihood of precip-
itating an immune response because of the smaller size
compared to human engineered viral vectors.22Red-green colorblindness
Gene therapy to cure red–green color blindness is in ad-
vance stage because of success in treating squirrel mon-
110 F.I. Al-Saikhankeys.23 Red–green color blindness affects one out of twelve
men and one out of two hundred and thirty women.23 Squir-
rel monkeys are preferred in this experiment because they
are naturally red–green color blind. Researchers at the Uni-
versity of Washington, Department of Ophthalmology
proved that gene therapy is able to cure red–green color
blindness in squirrel monkeys. The treatment of the disorder
entailed injecting the monkeys with a virus that had been
modified to deliver corrective gene to the monkeys.
However, researchers have faced numerous challenges in
their bid to use the therapy to treat red–green color blind-
ness in humans. These challenges include legal hurdles, and
financial challenges. Hence, it is pivotal for industrial partners
to invest in projects to achieve success. Therefore, clinical tri-
als for therapy are in the planning stage.23
The success of the therapy raised questions about funda-
mental assumptions about neural development and mental
perception because it was believed that this therapy could
only be successful in young specimens.Age related macular degeneration
Age related macular degeneration (AMD) is a chief cause
of blindness in the elderly, particularly those over 60 years
old.24 Gene therapy using CD59 seems to be capable of slow-
ing the progression of AMD. Researchers from Tufts Univer-
sity School of Medicine proved that CD59 administered
through gene therapy caused a significant reduction of
uncontrolled blood vessel growth as well as dead cells that
cause AMD.24 AMD is caused by an activation of membrane
attack complex (MAC), which kills cells in the back of the eye,
causing AMD. CD59 reduces the development of MAC. The
researchers found that CD59 could be delivered to the eye
of the patient using a virus that is similar to one used in hu-
mans. The findings show that CD59 reduced MAC develop-
ment by 62%.24 Another implication in the treatment of
AMD is that unlike the current mode of treatment, where
the patient undergoes frequent injections directly in the
eye, gene therapy is less frequent therefore reducing patient
discomfort and the risk of infections. The researchers have
not performed clinical trials on the use of CD59 in treating
AMD. However, they have formed a partnership with Hamera
Biosciences, Inc., in a bid to get the required funding.24Primary open angle glaucoma (POAG)
Primary open angle glaucoma (POAG) is a major cause of
global irreversible blindness.25 Currently there are no effec-
tive remedies for POAG. MYOC encoding myocilin creates
causal mutations and results in elevated intraocular pressure,
which in turn causes glaucoma. Gene therapy that cultures
Human Trabecular meshwork (HTM) cells encourages pro-
duction of mutant myocilin, and therefore normalizes cell
morphology and halting cell mortality. RNAi is used in elimi-
nating malformed myocilin HTM cells as a gene silencing
method. The first study to demonstrate that gene therapy
can be used in silencing mutant MYOC was performed in
2009 by Li et al.25 Previous studies were aimed at introducing
replacement cells to replace the damaged cells. MYOC-null
individuals have remained healthy after the therapy. Addi-
tionally the therapy is capable of suppressing myosin withoutthe need to replace damaged cells; hence, it is economical
and can be used in the treatment of other disorders.
Conclusion
Research into the potential application of gene therapy in
the treatment of various ophthalmic conditions produced
encouraging results. Many of the studies to date have utilized
animal models. The use of AVV vectors has facilitated the
transfer of normal genes into animal cells for models with
Leber’s Congenital Amaurosis, retinitis pigmentosa and Star-
gardt disease. Gene therapy for the treatment of red–green
colorblindness has been successful in squirrel monkeys. Plans
are at an advanced stage to start clinical trials. Researchers
have also proved that CD59 can treat AMD. Gene therapy
can be used to treat primary open angle glaucoma (POAG),
and studies have confirmed the economic viable. It has been
noted that these conditions are caused by mutations in spe-
cific genes which impair the production of essential proteins.
The fundamental principle behind gene therapy in ophthal-
mology is that the injection of fully-functional genes into cells
allows restoration of normal gene expression. Consequently,
the required gene product will be produced thus preventing
the escalation of a disease. However, the time requirement
for human clinical trials results of gene therapy will take some
time prior to routine use in patients.
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